Vertex pays Orna $65M to work on next-gen gene therapies for blood disorders

Vertex Pharmaceuticals is hoping to build upon its existing rare blood disease treatment portfolio, teaming up with Orna Therapeutics’ ReNAgade in efforts to develop next-gen gene therapies for sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT).